Clene reports Q2 net loss $7.4M, cash $7.3M, plans NDA submission for CNM-Au8 in ALS by end of 2025

Clene Inc.

Net loss of $7.4M ($0.78 per share) vs $6.8M ($1.06) in Q2 2024; R&D expenses $3.5M, G&A $2.4M.
Cash and equivalents $7.3M as of June 30, 2025; post-quarter $1.9M equity and $1.5M convertible debt funding provides runway into Q1 2026.
FDA meetings scheduled: Type C for survival data in Q3 2025, and analysis of NfL biomarker from NIH EAP early Q4 2025.
Plans to submit NDA for CNM-Au8 in ALS under accelerated approval by end of 2025.
End-of-Phase 2 Type B meeting with FDA for MS program planned in Q3 2025.

item 1.01item 2.02item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.